Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK2 | P49760 | 1/20 | 0.51 |
| ▸ | CLK3 | P49761 | 1/20 | 0.51 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.51 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 6/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.45 |
| ▸ | IKBKB | O14920 | 1/20 | 0.45 |
| ▸ | CHUK | O15111 | 1/20 | 0.45 |
| ▸ | ICOSLG | O75144 | 1/20 | 0.45 |
| ▸ | PIM1 | P11309 | 1/20 | 0.45 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.45 |
| ▸ | IKBKG | Q9Y6K9 | 1/20 | 0.45 |
| ▸ | ICOS | Q9Y6W8 | 1/20 | 0.45 |
| ▸ | STK33 | Q9BYT3 | 1/20 | 0.44 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.44 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12661886 | 0.89 | PARP1 (0.54) | CLK2CLK3DYRK1AMEN1KMT2A | |
| SCHEMBL12662006 | 0.87 | SMN1; SMN2 (0.45) | MEN1KMT2AMAPK1TRPV1TSHR | |
| SCHEMBL12661937 | 0.85 | CLK2 (0.57) | CLK2CLK3DYRK1AMEN1KMT2A | |
| SCHEMBL12662004 | 0.84 | PARP1 (0.46) | MEN1KMT2ATRPV1CHUKICOSLG | |
| SCHEMBL12673330 | 0.82 | KCNMA1 (0.52) | CLK2KCNMA1MEN1KMT2ARXFP1 | |
| SCHEMBL12673112 | 0.80 | RXFP1 (0.58) | CLK2CLK3DYRK1AMEN1KMT2A | |
| SCHEMBL12662003 | 0.80 | TRPV1 (0.43) | MEN1KMT2ATRPV1PIM1STK33 | |
| SCHEMBL12662449 | 0.80 | KDM4E (0.45) | MEN1KMT2AHTTKDM4EALDH1A1 | |
| SCHEMBL12673080 | 0.77 | PARP1 (0.51) | CLK2DYRK1AKCNMA1HTTMAPK1 | |
| SCHEMBL12661885 | 0.77 | PARP1 (0.53) | MEN1KMT2ATRPV1TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2315763-B1 | BENZIMIDAZOLES AND RELATED ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC (US) | 2016-06-01 | — | — | EP | disclosed |
| US-20150057272-A1 | BENZIMIDAZOLES AND RELATED ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC (US) | 2015-02-26 | — | — | US | disclosed |
| US-20150057272-A1 | BENZIMIDAZOLES AND RELATED ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC (US) | 2015-02-26 | — | — | US | disclosed |
| US-20110124637-A1 | BENZIMIDAZOLES AND RELATED ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2011-05-26 | — | — | US | disclosed |
| US-20110124637-A1 | BENZIMIDAZOLES AND RELATED ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2011-05-26 | — | — | US | disclosed |
| WO-2010003048-A1 | BENZIMIDAZOLES AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2010-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124637-A1 | BENZIMIDAZOLES AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRT3, SIRT1, SIRT2 | CLK2 381/4885CLK3 1037/4885DYRK1A 3654/4885 |
| US-20150057272-A1 | BENZIMIDAZOLES AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRT3, SIRT1, SIRT2 | CLK2 309/4885CLK3 716/4885DYRK1A 2852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.